When should a COVID‑19 positive patient be started on antibiotics?

When to Start Antibiotics in COVID-19 Positive Patients

Antibiotics should generally be withheld in COVID-19 patients upon admission unless they are critically ill requiring ICU care, have radiological findings or inflammatory markers strongly suggesting bacterial co-infection, or are severely immunocompromised. 1

Restrictive Antibiotic Strategy for Most Patients

• Do not prescribe antibiotics routinely for mild to moderately ill COVID-19 patients at admission, as bacterial co-infection rates are extremely low (less than 3% in emergency department presentations and 7-8% in hospitalized populations). 1

• The WHO explicitly recommends against empiric antibiotics in mild COVID-19 and advises against them in moderate disease unless there is clinical concern for bacterial pneumonia. 1

• Bacterial co-infection upon hospital admission occurs in only 1-8% of COVID-19 patients based on multiple cohort studies. 1

Specific Exceptions Requiring Antibiotic Initiation

Critically Ill Patients

• Start empiric antibiotics immediately for patients requiring ICU admission, mechanical ventilation, or presenting with septic shock while awaiting culture results. 1, 2

• These patients have higher risk of rapid deterioration from untreated bacterial infection and warrant coverage per standard sepsis protocols. 1

Radiological Evidence of Bacterial Co-infection

• Initiate antibiotics when chest imaging shows consolidation, sinus opacification, air-fluid levels, or new infiltrates that are distinctly compatible with bacterial pneumonia rather than viral changes alone. 1, 2

• Pitfall to avoid: Viral COVID-19 pneumonia itself causes infiltrates on imaging; do not reflexively start antibiotics based on radiographic changes without considering the clinical context. 3

Laboratory Markers Suggesting Bacterial Infection

• Consider antibiotics when patients demonstrate procalcitonin >0.5 ng/mL, significantly elevated C-reactive protein, or elevated white blood cell count in conjunction with clinical deterioration. 2, 3

• Critical caveat: Inflammatory markers are frequently elevated in severe COVID-19 without bacterial infection; biomarkers alone should not determine antibiotic initiation in non-critically ill patients. 1, 2

• One UK study showed that withholding antibiotics when procalcitonin <0.25 ng/mL reduced antibiotic use by more than two-fold without increasing mortality. 1

Immunocompromised Patients

• Start empiric antibiotics in patients receiving chemotherapy, with bone marrow or organ transplantation, immune deficiencies, poorly controlled HIV/AIDS, or on prolonged corticosteroids/immunosuppressives, as they may deteriorate rapidly with untreated bacterial infection. 1

Mandatory Diagnostic Workup Before Starting Antibiotics

• Obtain blood cultures, sputum cultures, and pneumococcal urinary antigen testing before initiating empiric therapy in all patients meeting criteria for suspected bacterial co-infection. 1, 2

• Perform Legionella urinary antigen testing according to local community-acquired pneumonia (CAP) guidelines. 1

• This comprehensive microbiologic workup is essential because it enables appropriate targeting and de-escalation of therapy. 2, 3

Antibiotic Selection When Indicated

• Follow local or national CAP guidelines for empiric regimen selection based on disease severity. 1

• For mild to moderate CAP: amoxicillin is typically recommended. 1

• For severe CAP on general wards: second or third-generation cephalosporins are appropriate. 1

• For critically ill patients or those with risk factors for Pseudomonas: consider antipseudomonal agents like cefepime, with possible double coverage based on local epidemiology. 3

• Do not routinely cover atypical pathogens (Legionella, Mycoplasma) in hospitalized COVID-19 patients, as these co-infections are rarely reported. 1

Antibiotic Stewardship and Duration

• Stop antibiotics after 48 hours if blood and sputum cultures show no bacterial pathogens and urinary antigen tests are negative. 1, 2, 3

• Limit treatment duration to 5 days when bacterial infection is confirmed and the patient shows improvement in signs, symptoms, and inflammatory markers. 1, 2, 3

• Reassess antibiotic necessity daily to enable de-escalation or discontinuation. 1

Common Pitfalls to Avoid

• Avoid reflexive antibiotic prescribing based solely on fever, elevated inflammatory markers, or radiographic infiltrates, as these occur commonly in COVID-19 without bacterial infection. 1, 2

• Do not continue antibiotics beyond 48 hours when cultures are negative and clinical improvement is evident. 3

• Recognize that overuse of antibiotics drives antimicrobial resistance, Clostridioides difficile infection, adverse drug reactions including nephrotoxicity and QT prolongation. 2, 4

• Secondary bacterial infections (hospital-acquired or ventilator-associated pneumonia) occur in up to 20% of hospitalized COVID-19 patients, particularly those on prolonged ventilation, requiring separate consideration from admission co-infection. 1, 3